GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:18 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.96 USD
-0.25 (-0.64%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $38.98 +0.02 (0.05%) 7:18 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GSK) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
by Zacks Equity Research
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
by Kinjel Shah
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
by Zacks Equity Research
J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.
Here's Why You Should Add Thermo Fisher to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
by Zacks Equity Research
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.
AstraZeneca/Merck's Lynparza Improves PFS in Frontline Study
by Zacks Equity Research
AstraZeneca's (AZN) Lynparza reduces the risk of disease progression by 41% in a study, evaluating the PARP inhibitor as a first-line maintenance treatment in women with advanced ovarian cancer.
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, GlaxoSmithKline, Duke and BlackRock
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, GlaxoSmithKline, Duke and BlackRock
Clovis Gains Rights to Pre-Clinical Cancer Program for $12M
by Zacks Equity Research
Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.
Top Stock Reports for Facebook, UnitedHealth & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth Group (UNH) and GlaxoSmithKline (GSK).
Glaxo's Benlysta Gets Positive CHMP Opinion for Use in Kids
by Zacks Equity Research
Glaxo's (GSK) SLE drug Benlysta gets a favorable CHMP opinion that recommends an approval for intravenous formulation in pediatric patients.
Merck's Two HIV Drugs Get FDA Approval for Expanded Use
by Zacks Equity Research
Merck's (MRK) new HIV drugs, Pifeltro and Delstrigo, get FDA nod for use in treatment-experienced adults living with HIV-1 who are virologically suppressed.
Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
by Zacks Equity Research
Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
by Zacks Equity Research
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
by Kinjel Shah
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?
by Zacks Equity Research
Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.